Recursion Pharmaceuticals, LLC, is a Salt Lake City-based drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition known drugs and shelved pharmaceutical assets to treat rare genetic diseases and other conditions. The company's original focus on rare genetic diseases is much needed, as there are more than 5,000 such conditions that together affect millions of Americans, and more than 95 percent of these diseases have no approved therapy. Recursion's novel drug screening platform combines experimental biology and bioinformatics in a massively parallel system to quickly and efficiently identify treatments for multiple rare genetic diseases, or any disease that can be modeled at the cellular level. The core of the approach revolves around high-throughput automated screening using high-content assays in human cells, which allows the near simultaneous modeling of hundreds of genetic and other diseases. Rich data from these assays is probed using advanced statistical and machine learning approaches, and the effects of thousands of known drugs, shelved drug candidates, and novel chemical matter can be investigated efficiently to identify those holding the most promise for the treatment of disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/03/16 | $12,900,000 | Series A |
AME Cloud Ventures Data Collective EPIC Ventures Lux Capital Obvious Ventures Wild Basin Investments | undisclosed |
| 11/22/16 | $2,150,000 | Series A |
Felicis Ventures | undisclosed |
| 10/03/17 | $60,000,000 | Series B |
Data Collective | undisclosed |
| 07/16/19 | $121,000,000 | Series C |
Baillie Gifford Data Collective EPIC Ventures Felicis Ventures Intermountain Ventures Lux Capital Menlo Ventures Mubadala Ventures Obvious Ventures Regents of the University of Minnesota Texas Tech University System Two Sigma Ventures | undisclosed |
| 09/11/20 | $239,000,000 | Series D |
Baillie Gifford Casdin Capital Catalio Capital Management DCVC EPIC Ventures Felicis Ventures Laurion Capital Management Leaps by Bayer Lux Capital Mubadala Capital Obvious Ventures Samsara BioCapital | undisclosed |
